New drugs to treat skin and soft tissue infections

被引：6

作者：

Stein G.E. ^{[1
]}

机构：

[1] Department of Medicine, Michigan State University, East Lansing, MI 48824

来源：

Current Infectious Disease Reports | 2007年 / 9卷 / 5期

关键词：

Vancomycin; Linezolid; Daptomycin; Antimicrob Agent; Tigecycline;

D O I：

10.1007/s11908-007-0063-7

中图分类号：

学科分类号：

摘要：

Due to increasing antimicrobial resistance, a pressing need exists for new antibiotics to treat skin and soft tissue infections. Several newer agents such as tigecydine, daptomycin, and linezolid have been important additions for the treatment of multidrug-resistant pathogens. New drugs in development such as dalbavancin and ceftobiprole will further enhance our ability to treat mixed infections and improve patient compliance. These promising new antimicrobials will likely grow in importance as resistant bacterial strains increase in community-acquired infections. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：408 / 414

页数：6

共 50 条

[1]

Talbot G.H., Bradley J., Edwards J.E., Et al., Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America, Clin Infect Dis, 42, pp. 657-668, (2006)

[2]

Steenbergen J.N., Alder J., Thorne G.M., Tally F.P., Daptomycin: A lipopeptide antibiotic for the treatment of serious Gram-positive infections, J Antimicrob Chemother, 55, pp. 283-288, (2005)

[3]

Streit J.M., Jones R.N., Sader H.S., Daptomycin activity and spectrum: A worldwide sample of 6737 clinical Gram-positive organisms, J Antimicrob Chemother, 53, pp. 669-674, (2004)

[4]

Wise R., Gee T., Andrews J.M., Et al., Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers, Antimicrob Agents Chemother, 46, pp. 31-33, (2002)

[5]

Arbeit R.D., Maki D., Tally F.P., Et al., The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections, Clin Infect Dis, 38, pp. 1673-1681, (2004)

[6]

Lipsky B.A., Stoutenburgh U., Daptomycin for treating infected diabetic foot ulcers: Evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections, J Antimicrob Chemother, 55, pp. 240-245, (2005)

[7]

Shah P.M., lsaacs R.D., Ertapenem, the first of a new group of carbapenems, J Antimicrob Chemother, 52, pp. 538-542, (2003)

[8]

Wexler H.M., In vitro activity or ertapenem: Review of recent studies, J Antimicrob Chemother, 53, SUPPL. S2, pp. 11-21, (2004)

[9]

Nix D.E., Majumdar A.K., DiNubile M.J., Pharmacokinetics and pharmacodynamics of ertapenem: An overview for clinicians, J Antimicrob Chemother, 53, SUPPL. S2, pp. 23-28, (2004)

[10]

Laethem T., De Lepeleire I., McCrea J., Et al., Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers, Antimicrob Agents Chemother, 47, pp. 1439-1442, (2003)

← 1 2 3 4 5 →